Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections
暂无分享,去创建一个
[1] M. Borad,et al. Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination , 2022, npj Vaccines.
[2] Dan Li,et al. Toxoplasmosis vaccines: what we have and where to go? , 2022, npj Vaccines.
[3] H. Tinto,et al. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. , 2022, The Lancet. Infectious diseases.
[4] Jiaofeng Huang,et al. The association between Toxoplasma infection and mortality: the NHANES epidemiologic follow-up study , 2022, Parasites & vectors.
[5] J. F. R. Mello,et al. The use of viral vectors in vaccine development , 2022, NPJ vaccines.
[6] I. Khan,et al. Immune responses to Toxoplasma gondii. , 2022, Current opinion in immunology.
[7] M. Ndao,et al. A low dose adenovirus vectored vaccine expressing Schistosoma mansoni Cathepsin B protects from intestinal schistosomiasis in mice , 2022, EBioMedicine.
[8] C. Freire-de-Lima,et al. Immune Responses in Leishmaniasis: An Overview , 2022, Tropical medicine and infectious disease.
[9] A. Davison,et al. ICTV Virus Taxonomy Profile: Adenoviridae 2022 , 2022, The Journal of general virology.
[10] Eric A. Wilson,et al. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome , 2021, Science advances.
[11] S. Chaudhury,et al. A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults , 2021, PloS one.
[12] M. Ndao,et al. Promising Technologies in the Field of Helminth Vaccines , 2021, Frontiers in Immunology.
[13] D. Curiel,et al. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic , 2021, NPJ vaccines.
[14] E. Lavelle,et al. Mucosal vaccines — fortifying the frontiers , 2021, Nature Reviews Immunology.
[15] J. Vekemans,et al. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial , 2021, Frontiers in Immunology.
[16] G. Matlashewski,et al. A review of the leishmanin skin test: A neglected test for a neglected disease , 2021, PLoS neglected tropical diseases.
[17] H. Mizukami,et al. Liver-Directed AAV8 Booster Vaccine Expressing Plasmodium falciparum Antigen Following Adenovirus Vaccine Priming Elicits Sterile Protection in a Murine Model , 2021, Frontiers in Immunology.
[18] Anisuzzaman,et al. Host-Specific Serum Factors Control the Development and Survival of Schistosoma mansoni , 2021, Frontiers in Immunology.
[19] Ki-Back Chu,et al. Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development , 2021, Vaccines.
[20] B. Pulendran,et al. Emerging concepts in the science of vaccine adjuvants , 2021, Nature reviews. Drug discovery.
[21] G. Matlashewski,et al. Revival of Leishmanization and Leishmanin , 2021, Frontiers in Cellular and Infection Microbiology.
[22] M. Yazdanbakhsh,et al. Immunological Considerations for Schistosoma Vaccine Development: Transitioning to Endemic Settings , 2021, Frontiers in Immunology.
[23] S. Pandey,et al. Role of Cytokines in Experimental and Human Visceral Leishmaniasis , 2021, Frontiers in Cellular and Infection Microbiology.
[24] A. Pance. Diversify and Conquer: The Vaccine Escapism of Plasmodium falciparum , 2020, Microorganisms.
[25] Adebayo J. Molehin. Current Understanding of Immunity Against Schistosomiasis: Impact on Vaccine and Drug Development , 2020, Research and reports in tropical medicine.
[26] Jinfang Zhu,et al. CD4 T Helper Cell Subsets and Related Human Immunological Disorders , 2020, International journal of molecular sciences.
[27] J. Hafalla,et al. Immune responses to malaria pre-erythrocytic stages: Implications for vaccine development , 2020, Parasite immunology.
[28] J. Webster,et al. Toxoplasma gondii: An Underestimated Threat? , 2020, Trends in parasitology.
[29] V. Shinde,et al. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine , 2020, The New England journal of medicine.
[30] P. Kaye,et al. Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan , 2020, medRxiv.
[31] M. Lewis,et al. Host‐parasite dynamics in Chagas disease from systemic to hyper‐local scales , 2020, Parasite immunology.
[32] C. B. Palatnik-de-Sousa,et al. The Delay in the Licensing of Protozoal Vaccines: A Comparative History , 2020, Frontiers in Immunology.
[33] R. Bergquist,et al. Schistosomiasis—from immunopathology to vaccines , 2020, Seminars in Immunopathology.
[34] M. Gállego,et al. Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy , 2020, Tropical medicine & international health : TM & IH.
[35] Anisuzzaman,et al. Schistosomiasis and hookworm infection in humans: Disease burden, pathobiology and anthelmintic vaccines. , 2020, Parasitology international.
[36] E. Malchiodi,et al. Chagas disease vaccine design: the search for an efficient Trypanosoma cruzi immune-mediated control. , 2020, Biochimica et biophysica acta. Molecular basis of disease.
[37] A. Mesías,et al. Redox Balance Keepers and Possible Cell Functions Managed by Redox Homeostasis in Trypanosoma cruzi , 2019, Front. Cell. Infect. Microbiol..
[38] A. Molan,et al. Global status of Toxoplasma gondii infection: systematic review and prevalence snapshots. , 2019, Tropical biomedicine.
[39] Masahiro Yamamoto,et al. Innate, adaptive, and cell-autonomous immunity against Toxoplasma gondii infection , 2019, Experimental & Molecular Medicine.
[40] A. Khamesipour,et al. An overview of leishmanization experience: A successful control measure and a tool to evaluate candidate vaccines. , 2019, Acta tropica.
[41] Yasuhiro Suzuki. The immune system utilizes two distinct effector mechanisms of T cells depending on two different life cycle stages of a single pathogen, Toxoplasma gondii, to control its cerebral infection. , 2019, Parasitology international.
[42] C. Janse,et al. Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria , 2019, Infection and Immunity.
[43] R. Gazzinelli,et al. CXCR3 chemokine receptor guides Trypanosoma cruzi-specific T-cells triggered by DNA/adenovirus ASP2 vaccine to heart tissue after challenge , 2019, PLoS neglected tropical diseases.
[44] R. Sherkat,et al. Leishmania Vaccines Entered in Clinical Trials: A Review of Literature , 2019, International journal of preventive medicine.
[45] Kristian E. Swearingen,et al. Proteomic Analysis of Plasmodium Merosomes: The Link Between Liver and Blood Stages in Malaria , 2019, bioRxiv.
[46] Ning Jiang,et al. Vaccination with recombinant adenoviruses expressing Toxoplasma gondii MIC3, ROP9, and SAG2 provide protective immunity against acute toxoplasmosis in mice. , 2019, Vaccine.
[47] D. Ribeiro,et al. Therapeutical effects of vaccine from Trypanosoma cruzi amastigote surface protein 2 by simultaneous inoculation with live parasites , 2018, Journal of cellular biochemistry.
[48] R. Gazzinelli,et al. Therapeutic effects of vaccine derived from amastigote surface protein‐2 (ASP‐2) against Chagas disease in mouse liver , 2019, Cytokine.
[49] H. Smits,et al. Schistosome Egg Migration: Mechanisms, Pathogenesis and Host Immune Responses , 2018, Front. Immunol..
[50] P. Bejon,et al. First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children , 2018, PloS one.
[51] D. Curiel,et al. Capsid-Incorporation Strategy To Display Antigens for an Alternative Adenoviral Vector Vaccine Approach. , 2018, Molecular pharmaceutics.
[52] R. Sinden,et al. Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP , 2018, npj Vaccines.
[53] Michael R. Elliott,et al. Alarmin S100A11 initiates a chemokine response to the human pathogen Toxoplasma gondii , 2018, Nature Immunology.
[54] J. Clements,et al. The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT , 2018, mSphere.
[55] A. Hill,et al. CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria , 2018, Front. Immunol..
[56] Anisuzzaman,et al. A novel cell-free method to culture Schistosoma mansoni from cercariae to juvenile worm stages for in vitro drug testing , 2019, PLoS neglected tropical diseases.
[57] D. Gurarie,et al. Are We on Our Way to Achieving the 2020 Goals for Schistosomiasis Morbidity Control Using Current World Health Organization Guidelines? , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[58] S. Hensley,et al. The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4+ T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway. , 2018, Vaccine.
[59] Lei Zhang,et al. Construction of an Adenovirus Vaccine Expressing the Cross-reactive Antigen AMA1 for Neospora caninum and Toxoplasma gondii and Its Immune Response in an Animal Model , 2018, Iranian journal of parasitology.
[60] C. Maritz-Olivier,et al. Metazoan Parasite Vaccines: Present Status and Future Prospects , 2018, Front. Cell. Infect. Microbiol..
[61] Masahiro Yamamoto,et al. Host immune responses to Toxoplasma gondii , 2018, International immunology.
[62] A. Nicosia,et al. Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP , 2018, Scientific Reports.
[63] I. Humphreys,et al. Novel viral vectors in infectious diseases , 2017, Immunology.
[64] Min Zhang,et al. A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII. , 2017, Vaccine.
[65] B. Cissé,et al. Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial , 2017, Frontiers in Immunology.
[66] Juliana K. Wambua,et al. Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. , 2017, JCI insight.
[67] A. Lawrie,et al. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™. , 2017, Vaccine.
[68] R. Gazzinelli,et al. LFA-1 Mediates Cytotoxicity and Tissue Migration of Specific CD8+ T Cells after Heterologous Prime-Boost Vaccination against Trypanosoma cruzi Infection , 2017, Front. Immunol..
[69] Dan J Stein,et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, Lancet.
[70] I. A. Hajam,et al. Bacterial flagellin—a potent immunomodulatory agent , 2017, Experimental &Molecular Medicine.
[71] R. Longley,et al. Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria , 2017, Scientific Reports.
[72] K. Williamson,et al. New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission , 2017, Malaria Journal.
[73] J. McCarthy,et al. Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies , 2017, JCI insight.
[74] R. Cortese,et al. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH , 2017, PLoS neglected tropical diseases.
[75] A. Hill,et al. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine , 2017, Scientific Reports.
[76] H. Cong,et al. Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes , 2017, Parasite.
[77] M. Sedegah,et al. Development of replication-deficient adenovirus malaria vaccines , 2017, Expert review of vaccines.
[78] J. Dai,et al. Evaluation of protective efficacy induced by different heterologous prime-boost strategies encoding triosephosphate isomerase against Schistosoma japonicum in mice , 2017, Parasites & Vectors.
[79] B. Zheng,et al. Immuno-Efficacy of a T. gondii Secreted Protein with an Altered Thrombospondin Repeat (TgSPATR) As a Novel DNA Vaccine Candidate against Acute Toxoplasmosis in BALB/c Mice , 2017, Front. Microbiol..
[80] R. Cortese,et al. Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[81] A. Didierlaurent,et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines , 2017, Expert review of vaccines.
[82] C. Janse,et al. Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine , 2016, Infection and Immunity.
[83] B. Cissé,et al. Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal , 2016, PloS one.
[84] Shoujun Li,et al. Recombinant canine adenovirus type-2 expressing TgROP16 provides partial protection against acute Toxoplasma gondii infection in mice. , 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[85] P. Geldhof,et al. Host Th1/Th2 immune response to Taenia solium cyst antigens in relation to cyst burden of neurocysticercosis , 2016, Parasite immunology.
[86] Shruti S. Sakhare,et al. Epitope Capsid-Incorporation: A New Effective Approach for Vaccine Development for Chagas Disease , 2016, Pathogens & immunity.
[87] J. Albano,et al. Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits. , 2016, Vaccine.
[88] R. Bhadra,et al. Blimp-1–mediated CD4 T cell exhaustion causes CD8 T cell dysfunction during chronic toxoplasmosis , 2016, The Journal of experimental medicine.
[89] A. Hill,et al. Viral vectors as vaccine platforms: from immunogenicity to impact. , 2016, Current opinion in immunology.
[90] J. Lynch,et al. Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention , 2016, Seminars in Respiratory and Critical Care Medicine.
[91] R. Sinden,et al. Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP , 2016, Journal of Infectious Diseases.
[92] Yushi Yao,et al. Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens , 2016, Molecular therapy. Methods & clinical development.
[93] R. Cortese,et al. Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[94] J. Votýpka,et al. A Historical Overview of the Classification, Evolution, and Dispersion of Leishmania Parasites and Sandflies , 2016, PLoS neglected tropical diseases.
[95] Q. Matthews,et al. A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors , 2016, Viruses.
[96] D. Colley,et al. Workshop report: Schistosomiasis vaccine clinical development and product characteristics. , 2016, Vaccine.
[97] E. Carvalho,et al. The Role of Nitric Oxide and Reactive Oxygen Species in the Killing of Leishmania braziliensis by Monocytes from Patients with Cutaneous Leishmaniasis , 2016, PloS one.
[98] A. Hill,et al. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology , 2016, Scientific Reports.
[99] A. Hill,et al. Progress with viral vectored malaria vaccines: A multi-stage approach involving “unnatural immunity” , 2015, Vaccine.
[100] A. Blagborough,et al. Tailoring a Combination Preerythrocytic Malaria Vaccine , 2015, Infection and Immunity.
[101] R. Longley,et al. Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfUIS3, PfLSA1 and PfLSAP2 in Multiple Strains of Mice , 2015, PloS one.
[102] Huai-yu Zhou,et al. A Toxoplasma gondii vaccine encoding multistage antigens in conjunction with ubiquitin confers protective immunity to BALB/c mice against parasite infection , 2015, Parasites & Vectors.
[103] N. Arsenijević,et al. Differential Immunometabolic Phenotype in Th1 and Th2 Dominant Mouse Strains in Response to High-Fat Feeding , 2015, PloS one.
[104] T. Stratmann,et al. Cholera Toxin Subunit B as Adjuvant––An Accelerator in Protective Immunity and a Break in Autoimmunity , 2015, Vaccines.
[105] L. Rénia,et al. Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax , 2015, Front. Immunol..
[106] C. Janse,et al. Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates , 2015, Scientific Reports.
[107] C. O’Mahony,et al. Induction of CD8(+) T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine. , 2015, Vaccine.
[108] A. Nicosia,et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults , 2015, Science Translational Medicine.
[109] J. Dai,et al. Enhancement of Protective Efficacy through Adenoviral Vectored Vaccine Priming and Protein Boosting Strategy Encoding Triosephosphate Isomerase (SjTPI) against Schistosoma japonicum in Mice , 2015, PloS one.
[110] Shoujun Li,et al. Protective efficacy of recombinant canine adenovirus type-2 expressing TgROP18 (CAV-2-ROP18) against acute and chronic Toxoplasma gondii infection in mice , 2015, BMC Infectious Diseases.
[111] Cécile Crosnier,et al. A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys , 2015, Cell host & microbe.
[112] R. Gazzinelli,et al. A Human Type 5 Adenovirus-Based Trypanosoma cruzi Therapeutic Vaccine Re-programs Immune Response and Reverses Chronic Cardiomyopathy , 2015, PLoS pathogens.
[113] R. Cortese,et al. Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals , 2014, The Journal of infectious diseases.
[114] H. Tallima,et al. Why the radiation-attenuated cercarial immunization studies failed to guide the road for an effective schistosomiasis vaccine: A review , 2014, Journal of advanced research.
[115] T. Rades,et al. Subunit Vaccine Delivery , 2015, Advances in Delivery Science and Technology.
[116] A. Nicosia,et al. A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS , 2014, PloS one.
[117] R. Cortese,et al. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[118] H. Fausther-Bovendo,et al. Pre-existing immunity against Ad vectors , 2014, Human vaccines & immunotherapeutics.
[119] A. Hill,et al. Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure , 2014, PloS one.
[120] G. Cheng,et al. Evaluation of protective immune response in mice by vaccination the recombinant adenovirus for expressing Schistosoma japonicum inhibitor apoptosis protein , 2014, Parasitology Research.
[121] A. Nicosia,et al. Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[122] S. Plotkin,et al. History of vaccination , 2014, Proceedings of the National Academy of Sciences.
[123] S. Pratap,et al. Immunization with Hexon Modified Adenoviral Vectors Integrated with gp83 Epitope Provides Protection against Trypanosoma cruzi Infection , 2014, PLoS neglected tropical diseases.
[124] W. Secor,et al. Immunology of human schistosomiasis , 2014, Parasite immunology.
[125] C. King,et al. Human schistosomiasis , 2014, The Lancet.
[126] R. Gazzinelli,et al. Genetic Vaccination against Experimental Infection with Myotropic Parasite Strains of Trypanosoma cruzi , 2014, Mediators of inflammation.
[127] A. Folgori,et al. Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain , 2014, PloS one.
[128] R. Gazzinelli,et al. Clinical and Parasitological Protection in a Leishmania infantum-Macaque Model Vaccinated with Adenovirus and the Recombinant A2 Antigen , 2014, PLoS neglected tropical diseases.
[129] J. Flegr,et al. Toxoplasmosis – A Global Threat. Correlation of Latent Toxoplasmosis with Specific Disease Burden in a Set of 88 Countries , 2014, PloS one.
[130] A. Hill,et al. Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection , 2014, Immunology.
[131] R. Gazzinelli,et al. Adenovirus vector-induced CD8⁺ T effector memory cell differentiation and recirculation, but not proliferation, are important for protective immunity against experimental Trypanosoma cruzi Infection. , 2014, Human gene therapy.
[132] Shan Lu,et al. Construction and evaluation of replication-defective recombinant optimized triosephosphate isomerase adenoviral vaccination in Schistosoma japonicum challenged mice. , 2014, Vaccine.
[133] M. McAllister. Successful vaccines for naturally occurring protozoal diseases of animals should guide human vaccine research. A review of protozoal vaccines and their designs , 2014, Parasitology.
[134] J. McAuley. Congenital Toxoplasmosis. , 2014, Journal of the Pediatric Infectious Diseases Society.
[135] O. Billker,et al. Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites , 2013, Infection and Immunity.
[136] A. Folgori,et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation , 2013, Nature Communications.
[137] R. Gazzinelli,et al. Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1 , 2013, PloS one.
[138] D. C. Cara,et al. Vaccination Using Recombinants Influenza and Adenoviruses Encoding Amastigote Surface Protein-2 Are Highly Effective on Protection against Trypanosoma cruzi Infection , 2013, PloS one.
[139] R. Cortese,et al. Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults , 2013, PloS one.
[140] A. Hill,et al. Assessment of Immune Interference, Antagonism, and Diversion following Human Immunization with Biallelic Blood-Stage Malaria Viral-Vectored Vaccines and Controlled Malaria Infection , 2013, The Journal of Immunology.
[141] S. Ghosh,et al. Combined action of nucleic acid-sensing Toll-like receptors and TLR11/TLR12 heterodimers imparts resistance to Toxoplasma gondii in mice. , 2013, Cell host & microbe.
[142] Giuseppe Del Giudice,et al. The history of MF59® adjuvant: a phoenix that arose from the ashes , 2013, Expert review of vaccines.
[143] R. Gazzinelli,et al. Pathogen-Induced Proapoptotic Phenotype and High CD95 (Fas) Expression Accompany a Suboptimal CD8+ T-Cell Response: Reversal by Adenoviral Vaccine , 2012, PLoS pathogens.
[144] A. Machado,et al. Re-circulation of lymphocytes mediated by sphingosine-1-phosphate receptor-1 contributes to resistance against experimental infection with the protozoan parasite Trypanosoma cruzi. , 2012, Vaccine.
[145] F. Robert-Gangneux,et al. Epidemiology of and Diagnostic Strategies for Toxoplasmosis , 2012, Clinical Microbiology Reviews.
[146] P. Kaye,et al. Therapeutic Vaccination With Recombinant Adenovirus Reduces Splenic Parasite Burden in Experimental Visceral Leishmaniasis , 2012, The Journal of infectious diseases.
[147] S. Rafati,et al. CD8+ T Cells in Leishmania Infections: Friends or Foes? , 2012, Front. Immun..
[148] Xiao-Guang Chen,et al. A Review: Competence, Compromise, and Concomitance—Reaction of the Host Cell To Toxoplasma gondii Infection and Development , 2011, The Journal of parasitology.
[149] K. Mansfield,et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. , 2011, Vaccine.
[150] R. Gazzinelli,et al. Subdominant/Cryptic CD8 T Cell Epitopes Contribute to Resistance against Experimental Infection with a Human Protozoan Parasite , 2011, PloS one.
[151] R. Gazzinelli,et al. MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8(+) T lymphocytes. , 2011, Vaccine.
[152] R. Bhadra,et al. Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1–PDL-1 blockade , 2011, Proceedings of the National Academy of Sciences.
[153] N. Garçon,et al. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile , 2011, Expert opinion on biological therapy.
[154] P. Chomez,et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. , 2011, Vaccine.
[155] K. Matuschewski,et al. Cell biology and immunology of malaria , 2011, Immunological reviews.
[156] R. Gazzinelli,et al. Heterologous Plasmid DNA Prime-Recombinant Human Adenovirus 5 Boost Vaccination Generates a Stable Pool of Protective Long-Lived CD8+ T Effector Memory Cells Specific for a Human Parasite, Trypanosoma cruzi , 2011, Infection and Immunity.
[157] C. Hunter,et al. Regulation of CD8+ T cell responses to infection with parasitic protozoa. , 2010, Experimental parasitology.
[158] A. Vella,et al. Educating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide. , 2010, Trends in immunology.
[159] D. Metzger. Interleukin-12 as an adjuvant for induction of protective antibody responses. , 2010, Cytokine.
[160] N. Escriou,et al. Prime and boost immunization with influenza and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective immunity. , 2010, Vaccine.
[161] A. Folgori,et al. Prime-boost vectored malaria vaccines: Progress and prospects , 2010, Human vaccines.
[162] J. Heeney,et al. Viruses as vaccine vectors for infectious diseases and cancer , 2010, Nature Reviews Microbiology.
[163] F. Tzelepis,et al. Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection. , 2009, Vaccine.
[164] T. Richie,et al. Viral vectors in malaria vaccine development , 2009, Parasite immunology.
[165] R. Gazzinelli,et al. Perforin and Gamma Interferon Expression Are Required for CD4+ and CD8+ T-Cell-Dependent Protective Immunity against a Human Parasite, Trypanosoma cruzi, Elicited by Heterologous Plasmid DNA Prime-Recombinant Adenovirus 5 Boost Vaccination , 2009, Infection and Immunity.
[166] R. Tarleton,et al. Insufficient TLR Activation Contributes to the Slow Development of CD8+ T Cell Responses in Trypanosoma cruzi Infection1 , 2009, The Journal of Immunology.
[167] J. Dubey,et al. Toxoplasmosis in sheep--the last 20 years. , 2009, Veterinary parasitology.
[168] Shan Lu. Heterologous prime-boost vaccination. , 2009, Current opinion in immunology.
[169] P. Marrack,et al. Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.
[170] J. Daily,et al. Trypanosoma cruzi Triggers an Early Type I IFN Response In Vivo at the Site of Intradermal Infection1 , 2009, The Journal of Immunology.
[171] Gail M. Williams,et al. Transmission Dynamics of Schistosoma japonicum in the Lakes and Marshlands of China , 2008, PloS one.
[172] M. Mota,et al. Interactions of the malaria parasite and its mammalian host. , 2008, Current Opinion in Microbiology.
[173] Rino Rappuoli,et al. Bridging the knowledge gaps in vaccine design , 2007, Nature Biotechnology.
[174] V. Singh,et al. Immune response to leishmania: paradox rather than paradigm. , 2007, FEMS immunology and medical microbiology.
[175] D. Karanja,et al. T regulatory cell levels decrease in people infected with Schistosoma mansoni on effective treatment. , 2007, The American journal of tropical medicine and hygiene.
[176] J. Harty,et al. Viral vector vaccines make memory T cells against malaria , 2007, Immunology.
[177] G. Schares,et al. Epidemiology and Control of Neosporosis and Neospora caninum , 2007, Clinical Microbiology Reviews.
[178] A. Sher,et al. Cutting Edge: TLR9 and TLR2 Signaling Together Account for MyD88-Dependent Control of Parasitemia in Trypanosoma cruzi Infection1 , 2006, The Journal of Immunology.
[179] R. Gazzinelli,et al. Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. , 2006, Human gene therapy.
[180] S. G. Andrade,et al. Trypanosoma cruzi: clones isolated from the Colombian strain, reproduce the parental strain characteristics, with ubiquitous histotropism , 2006, International journal of experimental pathology.
[181] R. Gazzinelli,et al. Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of toxoplasma gondii induces immune response and protection against infection in mice. , 2006, Human gene therapy.
[182] Stefan Riedel,et al. Edward Jenner and the History of Smallpox and Vaccination , 2005, Proceedings.
[183] Hildegund C.J. Ertl,et al. Adenoviruses as vaccine vectors , 2004, Molecular Therapy.
[184] Chuan-Xin Yu,et al. The protective immunity of a DNA vaccine encoding Schistosoma japonicum Chinese strain triose-phosphate isomerase in infected BALB/C mice. , 2004, The Southeast Asian journal of tropical medicine and public health.
[185] J. Montoya,et al. Toxoplasmosis , 2004, The Lancet.
[186] Niels Brimnes. Variolation, Vaccination and Popular Resistance in Early Colonial South India , 2004, Medical History.
[187] D. Klinman. Immunotherapeutic uses of CpG oligodeoxynucleotides , 2004, Nature Reviews Immunology.
[188] P. Tsagozis,et al. CD8+ T cells with parasite‐specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis , 2003, Parasite immunology.
[189] E. Zijlstra,et al. Post-kala-azar dermal leishmaniasis. , 2003, The Lancet. Infectious diseases.
[190] D. Sacks,et al. The immunology of susceptibility and resistance to Leishmania major in mice , 2002, Nature Reviews Immunology.
[191] F. Cox,et al. History of Human Parasitology , 2002, Clinical Microbiology Reviews.
[192] Patricia De la Vega,et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. , 2002, The Journal of infectious diseases.
[193] M. Grijalva,et al. Mouse model for Chagas disease: immunohistochemical distribution of different stages of Trypanosoma cruzi in tissues throughout infection. , 2001, The American journal of tropical medicine and hygiene.
[194] J. Wilson,et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[195] L. Weiss,et al. Toxoplasma gondii: from animals to humans. , 2000, International journal for parasitology.
[196] T. Wynn,et al. IL-10 and the Dangers of Immune Polarization: Excessive Type 1 and Type 2 Cytokine Responses Induce Distinct Forms of Lethal Immunopathology in Murine Schistosomiasis , 2000, The Journal of Immunology.
[197] R. Tarleton,et al. Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. , 1999, The Journal of infectious diseases.
[198] T. Wynn,et al. Studies with double cytokine-deficient mice reveal that highly polarized Th1- and Th2-type cytokine and antibody responses contribute equally to vaccine-induced immunity to Schistosoma mansoni. , 1999, Journal of immunology.
[199] P. Coulson,et al. Strategies for a schistosome vaccine: can we manipulate the immune response effectively? , 1999, Microbes and infection.
[200] T. Govezensky,et al. Shift from an early protective Th1-type immune response to a late permissive Th2-type response in murine cysticercosis (Taenia crassiceps). , 1998, The Journal of parasitology.
[201] M. Plebanski,et al. Genetic analysis of host-parasite coevolution in human malaria. , 1997, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[202] J. Waterkeyn,et al. Sequential nucleic acid and recombinant adenovirus vaccination induces host‐protective immune responses against Taenia ovis infection in sheep , 1997, Parasite immunology.
[203] T. Slifer,et al. IL-10 is required to prevent immune hyperactivity during infection with Trypanosoma cruzi. , 1997, Journal of immunology.
[204] J. Sadoff,et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. , 1995, The Journal of infectious diseases.
[205] I. Charles,et al. Altered immune responses in mice lacking inducible nitric oxide synthase , 1995, Nature.
[206] D. Buxton,et al. A commercial vaccine for ovine toxoplasmosis , 1995, Parasitology.
[207] A. Hendrickx,et al. Experimental fetal and transplacental Neospora infection in the nonhuman primate. , 1994, Laboratory investigation; a journal of technical methods and pathology.
[208] C. Hunter,et al. Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha , 1994, Infection and immunity.
[209] D. Russell,et al. The interaction of Leishmania species with macrophages. , 1992, Advances in parasitology.
[210] J. Louis,et al. T-cell responses and immunity to experimental infection with leishmania major. , 1989, Annual review of immunology.
[211] J. Dubey,et al. Newly recognized fatal protozoan disease of dogs. , 1988, Journal of the American Veterinary Medical Association.
[212] B. Moss,et al. Live recombinant vaccinia virus protects chimpanzees against hepatitis B , 1984, Nature.
[213] F. Modabber,et al. Generalized infection and lack of delayed hypersensitivity in BALB/c mice infected with Leishmania tropica major , 1979, Infection and immunity.
[214] R. Ceredig,et al. Murine cutaneous leishmaniasis: disease patterns in intact and nude mice of various genotypes and examination of some differences between normal and infected macrophages. , 1979, The Australian journal of experimental biology and medical science.
[215] R. Melo,et al. Tissue tropism of different Trypanosoma cruzi strains. , 1978, The Journal of parasitology.
[216] L. K. Eveland,et al. Schistosoma mansoni: infectivity and immunizing effects of in vitro derived schistosomula attenuated by X irradiation. , 1978, Experimental parasitology.
[217] R. H. Jacobson,et al. Immunization of mice with cobalt-60 irradiated Schistosoma mansoni cercariae. , 1978, The American journal of tropical medicine and hygiene.